نتایج جستجو برای: cml

تعداد نتایج: 6124  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2017
Bei Jin Chengyan Wang Juan Li Xin Du Ke Ding Jingxuan Pan

PURPOSE Leukemia stem cells (LSC), which are insensitive to tyrosine kinase inhibitors (TKI), are an important source of TKI resistance and disease relapse in chronic myelogenous leukemia (CML). Obstacles to eradicating LSCs include limited understanding of the regulation network of LSCs. The current study aimed to examine the interplay between NF-κB and FOXM1/β-catenin, and the effect of its c...

2017
Franck E. Nicolini Grzegorz W. Basak Dong‐Wook Kim Eduardo Olavarria Javier Pinilla‐Ibarz Jane F. Apperley Timothy Hughes Dietger Niederwieser Michael J. Mauro Charles Chuah Andreas Hochhaus Giovanni Martinelli Maral DerSarkissian Mei Sheng Duh Lisa J. McGarry Hagop M. Kantarjian Jorge E. Cortes

BACKGROUND Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogene...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Irina Sadovnik Andrea Hoelbl-Kovacic Harald Herrmann Gregor Eisenwort Sabine Cerny-Reiterer Wolfgang Warsch Gregor Hoermann Georg Greiner Katharina Blatt Barbara Peter Gabriele Stefanzl Daniela Berger Martin Bilban Susanne Herndlhofer Heinz Sill Wolfgang R Sperr Berthold Streubel Christine Mannhalter Tessa L Holyoake Veronika Sexl Peter Valent

PURPOSE In chronic myelogenous leukemia (CML), leukemic stem cells (LSC) represent a critical target of therapy. However, little is known about markers and targets expressed by LSCs. The aim of this project was to identify novel relevant markers of CML LSCs. EXPERIMENTAL DESIGN CML LSCs were examined by flow cytometry, qPCR, and various bioassays. In addition, we examined the multipotent CD25...

1991
Emden R. Gansner John H. Reppy

Both the implementation and the user’s view of eXene rely heavily on the concurrency model provided by CML . CML is based on the sequential language SML[MTH90, MT91] and inherits the following good features of SML: functions as first-class values, strong static typing, polymorphism, datatypes and pattern matching, lexical scoping, exception handling and a state-of-the-art module facility. The s...

2008
N. I. Sandu N. I. SANDU

The structure of the commutative Moufang loops (CML) with minimum condition for subloops is examined. In particular it is proved that such a CML Q is a finite extension of a direct product of a finite number of the quasicyclic groups, lying in the centre of the CML Q. It is shown that the minimum conditions for subloops and for normal subloops are equivalent in a CML. Moreover, such CML also ch...

2016
Junil Kim Seong-Jin Kim Kazuhito Naka

Dipeptide species are accumulated in the chronic myelogenous leukemia (CML) stem cells [1]. To investigate the molecular mechanisms of the accumulation of dipeptide species in CML stem cells, we performed transcriptome sequencing of long-term stem cells, short-term stem cells, progenitor cells from healthy control and CML-affected mice (GSE70031). The transcriptome data revealed that the expres...

Journal: :Internal medicine 2014
Tomohiro Kajiguchi Shingo Okuno Toshihito Ohno Akihiro Abe

The BCR-ABL1 fusion gene is the molecular marker of chronic myeloid leukemia (CML). The e19a2 transcript is a rare variant associated with various clinical presentations and courses of CML. We herein present a case of e19a2-positive CML who was intolerant to initial treatment with imatinib and successfully responded to subsequent nilotinib therapy. She achieved a major molecular response and ha...

2014
Yosuke Minami

Chronic Myeloid Leukemia (CML) is effectively treated with Tyrosine Kinase Inhibitors (TKI) such as Imatinib Mesylate (IM) targeted against BCR-ABL, however, several mathematical models and ex vivo-examinations suggested that IM does not eradicate CML stem cells. We previously reported the investigation of residual CML diseases during TKI treatment using FACS-sorting and quantitative RT-PCR of ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2004
Daniel J DeAngelo Ephraim P Hochberg Edwin P Alyea Janina Longtine Stephanie Lee Ilene Galinsky Ben Parekkedon Jerome Ritz Joseph H Antin Richard M Stone Robert J Soiffer

PURPOSE Over the last several years, donor lymphocyte infusions have become the standard approach for patients with chronic myelogenous leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT). Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses. EXPERIMENT...

2016
Mustafa Yilmaz Beyhan Guvercin Ceren Konca

Chronic myeloid leukemia (CML) is generally diagnosed through findings such as marked leukocytosis at full blood count or splenomegaly at physical examination, while isolated thrombocytosis is not an expected condition. This paper examines hematological values, clinical findings, cytogenetic and molecular genetic data from 3 cases of CML presenting with isolated thrombocytosis. In addition, pot...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید